| Segment Information |
17. Segment Information
The Company’s operations involve the development and usage, including licensing, of DehydraTECH. Lexaria is centrally managed and its chief operating decision makers, being the President and the CEO, use the consolidated and other financial information supplemented by revenue information by category of business-to-business product production and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. Licensing revenues are concentrated on three licensees.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated |
|
Year Ended August 31, 2023 |
|
IP Licensing |
|
|
B2B Product |
|
|
R&D |
|
|
Corporate |
|
|
Total |
|
Revenue |
|
$ |
146,800 |
|
|
$ |
44,167 |
|
|
$ |
35,241 |
|
|
$ |
- |
|
|
$ |
226,208 |
|
Cost of goods sold |
|
|
- |
|
|
|
(31,500 |
) |
|
|
- |
|
|
|
- |
|
|
$ |
(31,500 |
) |
Operating expenses |
|
|
(70,677 |
) |
|
|
(282,709 |
) |
|
|
(3,666,721 |
) |
|
|
(2,708,623 |
) |
|
$ |
(6,728,730 |
) |
Other income/(expense) |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
(178,503 |
) |
|
$ |
(178,503 |
) |
Segment loss |
|
$ |
76,123 |
|
|
$ |
(270,042 |
) |
|
$ |
(3,631,480 |
) |
|
$ |
(2,887,126 |
) |
|
$ |
(6,712,525 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
103,336 |
|
|
$ |
65,573 |
|
|
$ |
187,532 |
|
|
$ |
2,729,545 |
|
|
$ |
3,083,986 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated |
|
Year Ended August 31, 2022 |
|
IP Licensing |
|
|
B2B Product |
|
|
R&D |
|
|
Corporate |
|
|
Total |
|
Revenue |
|
$ |
54,560 |
|
|
$ |
113,438 |
|
|
$ |
54,800 |
|
|
$ |
32,599 |
|
|
$ |
255,397 |
|
Cost of goods sold |
|
|
- |
|
|
|
(71,841 |
) |
|
|
- |
|
|
|
- |
|
|
$ |
(71,841 |
) |
Operating expenses |
|
|
(307,809 |
) |
|
|
(731,427 |
) |
|
|
(1,842,675 |
) |
|
|
(4,685,298 |
) |
|
$ |
(7,567,209 |
) |
Segment loss |
|
$ |
(253,249 |
) |
|
$ |
(689,830 |
) |
|
$ |
(1,787,875 |
) |
|
$ |
(4,652,699 |
) |
|
$ |
(7,383,653 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
161,307 |
|
|
$ |
205,956 |
|
|
$ |
247,345 |
|
|
$ |
7,219,319 |
|
|
$ |
7,833,927 |
|
|
Capital Asset by Region
Year Ended August 31, 2023
|
|
Cost
US
|
|
|
Addition
US
|
|
|
Net Balance
US
|
|
|
Cost
Canada
|
|
|
Addition
Canada
|
|
|
Net Balance Canada |
|
|
Total Net Balance |
|
Leasehold Improvements |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
259,981 |
|
|
$ |
- |
|
|
$ |
11,258 |
|
|
$ |
11,258 |
|
Computers |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
70,781 |
|
|
|
- |
|
|
|
4,625 |
|
|
|
4,625 |
|
Furniture & Fixtures |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
31,126 |
|
|
|
- |
|
|
|
1,869 |
|
|
|
1,869 |
|
Lab Equipment |
|
|
140,490 |
|
|
|
33,748 |
|
|
|
122,855 |
|
|
|
193,185 |
|
|
|
- |
|
|
|
113,536 |
|
|
|
236,391 |
|
|
|
$ |
140,490 |
|
|
$ |
33,748 |
|
|
$ |
122,855 |
|
|
$ |
555,073 |
|
|
$ |
- |
|
|
$ |
131,288 |
|
|
$ |
254,143 |
|
|
Capital Asset by Region
Year Ended August 31, 2022
|
|
Cost
US
|
|
|
Addition
US
|
|
|
Net Balance
US
|
|
|
Cost
Canada
|
|
|
Addition
Canada
|
|
|
Net Balance Canada |
|
|
Total Net Balance |
|
Leasehold Improvements |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
259,981 |
|
|
$ |
- |
|
|
$ |
65,296 |
|
|
$ |
65,296 |
|
Computers |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
63,964 |
|
|
|
6,817 |
|
|
|
9,357 |
|
|
|
9,357 |
|
Furniture & Fixtures |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
31,126 |
|
|
|
- |
|
|
|
8,288 |
|
|
|
8,288 |
|
Lab Equipment |
|
|
98,050 |
|
|
|
42,375 |
|
|
|
100,031 |
|
|
|
193,185 |
|
|
|
- |
|
|
|
132,533 |
|
|
|
232,564 |
|
|
|
$ |
98,050 |
|
|
$ |
42,375 |
|
|
$ |
100,031 |
|
|
$ |
548,256 |
|
|
$ |
6,817 |
|
|
$ |
215,474 |
|
|
$ |
315,505 |
|
|